Literature DB >> 22130369

Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis.

Zhi-Bo Xing1, Lei Yao, Guo-Qiang Zhang, Xian-Yu Zhang, You-Xue Zhang, Da Pang.   

Abstract

Radix Stephaniae tetrandrae, which contains tetrandrine (Tet) and fangchinoline, is traditionally used as an analgesic, antirheumatic, and antihypertensive drug in China. In this study, we investigated its effect on breast cancer cell proliferation and its potential mechanism of action in vitro. Treatment of cells with fangchinoline significantly inhibited MDA-MB-231 cell proliferation in a concentration- and time-dependent manner. To define the mechanism underlying the antiproliferative effects of fangchinoline, we studied its effects on critical molecular events known to regulate the apoptotic machinery. Specifically, we addressed the potential of fangchinoline to induce apoptosis of breast cancer cells. Fangchinoline induced internucleosomal DNA fragmentation, chromatin condensation, activation of caspases-3, -8, and -9, and cleavage of poly(ADP ribose) polymerase, as well as enhanced mitochondrial cytochrome c release. Furthermore, fangchinoline increased the expression of the proapoptotic protein B cell lymphoma-2 associated X (Bax) and decreased the expression of the antiapoptotic protein B cell lymphoma-2 (Bcl-2). In addition, the proliferation-inhibitory effect of fangchinoline was associated with decreased levels of phosphorylated Akt. Our results indicate that fangchinoline can inhibit breast cancer cell proliferation by inducing apoptosis via the mitochondrial apoptotic pathway and decreasing phosphorylated Akt. Thus fangchinoline may be a novel agent that can potentially be developed clinically to target human malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130369     DOI: 10.1248/cpb.59.1476

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  8 in total

1.  Fangchinoline inhibits the proliferation of SPC-A-1 lung cancer cells by blocking cell cycle progression.

Authors:  Xue Luo; Jian-Ming Peng; Lan-DI Su; Dong-Yan Wang; You-Jiang Yu
Journal:  Exp Ther Med       Date:  2015-12-04       Impact factor: 2.447

2.  Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades.

Authors:  Bingyu Guo; Peng Xie; Jingyuan Su; Tingting Zhang; Xiaoming Li; Guobiao Liang
Journal:  Tumour Biol       Date:  2015-09-25

3.  Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells.

Authors:  Feng Tian; Ding Ding; Dandan Li
Journal:  Int J Oncol       Date:  2015-04-09       Impact factor: 5.650

4.  Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.

Authors:  Dong Li; Yu Lu; Peng Sun; Li-Xing Feng; Miao Liu; Li-Hong Hu; Wan-Ying Wu; Bao-Hong Jiang; Min Yang; Xiao-Bo Qu; De-An Guo; Xuan Liu
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

5.  Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis.

Authors:  Jiandong Li; Wenda Cen; Chenhao Tong; Luna Wang; Weiguang Zhang; Shiqing Deng; Jianhua Yu; Baochun Lu
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

6.  Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.

Authors:  Yuping Wang; Jie Chen; Lin Wang; Yuji Huang; Ye Leng; Guiying Wang
Journal:  Exp Ther Med       Date:  2013-01-24       Impact factor: 2.447

Review 7.  Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy.

Authors:  Ting Liu; Xin Liu; Wenhua Li
Journal:  Oncotarget       Date:  2016-06-28

8.  Fangchinoline suppresses growth and metastasis of melanoma cells by inhibiting the phosphorylation of FAK.

Authors:  Jie Shi; Bingyu Guo; Qiang Hui; Peng Chang; Kai Tao
Journal:  Oncol Rep       Date:  2017-05-30       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.